{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:38:12Z","timestamp":1789472292362,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.pharmthera.2022.108294","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:25:32Z","timestamp":1664493932000},"page":"108294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"240","author":[{"given":"Xenophon","family":"Theodoridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kalopitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vadarlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra Rafailia","family":"Bakaloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u039dikolaos","family":"Gkiourtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Dionysopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Karanika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Tsekitsidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Chourdakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pharmthera.2022.108294_bb0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","article-title":"Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver","volume":"81","author":"Akcam","year":"2011","journal-title":"International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- Und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108294_bb0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4274\/jcrpe.1749","article-title":"Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease","volume":"7","author":"Boyraz","year":"2015","journal-title":"Journal of Clinical Research in Pediatric Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.clnu.2016.12.009","article-title":"Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Chen","year":"2018","journal-title":"Clinical Nutrition (Edinburgh, Scotland)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108294_bb0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40272-018-0292-2","article-title":"Nonalcoholic fatty liver disease in children: Not a small matter","volume":"20","author":"Conjeevaram Selvakumar","year":"2018","journal-title":"Paediatric Drugs"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108294_bb0040","article-title":"Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: Results from a single centre trial","volume":"11","author":"Corte","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"7109","key":"10.1016\/j.pharmthera.2022.108294_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108294_bb6000","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108294_bb0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1651-2227.2007.00429.x","article-title":"Liver dysfunction in paediatric obesity: A randomized, controlled trial of metformin","volume":"96","author":"Freemark","year":"2007","journal-title":"Acta Paediatrica (Oslo, Norway: 1992)"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108294_bb0060","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17795\/compreped-6249","article-title":"Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease","volume":"4","author":"Ghergherehchi","year":"2012","journal-title":"Journal of Comprehensive Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.47203\/IJCH.2019.v31i01.009","article-title":"Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease","volume":"31","author":"Goyal","year":"2019","journal-title":"Indian Journal of Community Health"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108294_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108294_bb3000","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","article-title":"Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial","volume":"166","author":"Janczyk","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2022.108294_bb0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1758-5996-1-29","article-title":"Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents","volume":"1","author":"Kelishadi","year":"2009","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"16","key":"10.1016\/j.pharmthera.2022.108294_bb0090","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108294_bb0095","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/gut.2007.142919","article-title":"Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis","volume":"57","author":"Manco","year":"2008","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1627456","article-title":"Nonalcoholic fatty liver disease in children","volume":"38","author":"Mann","year":"2018","journal-title":"Seminars in Liver Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0105","first-page":"13","article-title":"Hydroxytyrosol: Health benefits and use as functional ingredient in meat","volume":"5","author":"Mart\u00ednez","year":"2018","journal-title":"Medicines (Basel, Switzerland)"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108294_bb0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/nutrit\/nuy022","article-title":"Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease","volume":"76","author":"Musa-Veloso","year":"2018","journal-title":"Nutrition Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5448.2008.00450.x","article-title":"Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents","volume":"10","author":"Nadeau","year":"2009","journal-title":"Pediatric Diabetes"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108294_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Medicine"},{"issue":"11-12","key":"10.1016\/j.pharmthera.2022.108294_bb4000","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1365-2036.2006.03161.x","article-title":"Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease","volume":"24","author":"Nobili","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108294_bb0125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","article-title":"Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children","volume":"23","author":"Nobili","year":"2013","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases: NMCD"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/ars.2018.7704","article-title":"The antioxidant effects of Hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: A new treatment?","volume":"31","author":"Nobili","year":"2019","journal-title":"Antioxidants & Redox Signaling"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108294_bb0135","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108294_bb0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.2010.192401","article-title":"Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial","volume":"96","author":"Nobili","year":"2011","journal-title":"Archives of Disease in Childhood"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108294_bb0145","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.clinthera.2008.06.012","article-title":"Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study","volume":"30","author":"Nobili","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hep.22336","article-title":"Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial","volume":"48","author":"Nobili","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108294_bb0155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","article-title":"A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease","volume":"25","author":"Pacifico","year":"2015","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases: NMCD"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108294_bb0160","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/ajg.2010.152","article-title":"Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease","volume":"105","author":"Patton","year":"2010","journal-title":"The American Journal of Gastroenterology"},{"issue":"25","key":"10.1016\/j.pharmthera.2022.108294_bb0165","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4254\/wjh.v7.i25.2597","article-title":"Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future","volume":"7","author":"Rahimlou","year":"2015","journal-title":"World Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108294_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108294_bb0180","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","article-title":"A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis","volume":"21","author":"Schwimmer","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108294_bb0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCULATIONAHA.107.739920","article-title":"Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease","volume":"118","author":"Schwimmer","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108294_bb0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action","volume":"64","author":"Scorletti","year":"2018","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108294_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2431-13-115","article-title":"Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth","volume":"13","author":"Silveira","year":"2013","journal-title":"BMC Pediatrics"},{"key":"10.1016\/j.pharmthera.2022.108294_bb0200","first-page":"l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research Ed.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jgh.15221","article-title":"Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease","volume":"36","author":"Vadarlis","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108294_bb0210","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN hepatology committee","volume":"54","author":"Vajro","year":"2012","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108294_bb0215","first-page":"48","article-title":"Vitamin E treatment in pediatric obesity-related liver disease: A randomized study","volume":"38","author":"Vajro","year":"2004","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108294_bb0220","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108294_bb0225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the expert committee on NAFLD (ECON) and the north American Society of Pediatric Gastroenterology, hepatology and N","volume":"64","author":"Vos","year":"2017","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108294_bb2000","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3748\/wjg.14.1598","article-title":"Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children","volume":"14","author":"Wang","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"35","key":"10.1016\/j.pharmthera.2022.108294_bb0230","doi-asserted-by":"crossref","first-page":"25088","DOI":"10.1074\/jbc.M113.452516","article-title":"Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion","volume":"288","author":"Yadav","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108294_bb5000","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1139\/apnm-2016-0689","article-title":"Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial","volume":"42","author":"Z\u00f6hrer","year":"2017","journal-title":"Appl Physiol Nutr Metab"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:30:49Z","timestamp":1759012249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"alternative-id":["S0163725822001887"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108294","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108294"}}